ArticleJournal of the American Association for Laboratory Animal Science : JAALAS2025
Evaluation of Extended- and Immediate-Release Buprenorphine Formulations on Pharmacokinetics and Injection Site Lesions in Different Strains and Sex of Mice.
Article in Journal of the American Association for Laboratory Animal Science : JAALAS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pharmacokinetics and Analgesic Efficacy of a Novel Extended-Release Buprenorphine Formulation in Mice.Journal of the American Association for Laboratory Animal Science : JAALAS · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Buprenorphine is a commonly used analgesic in laboratory rodents for procedures of moderate to severe pain. We evaluated the pharmacokinetic properties of an immediate-release formulation of buprenorphine (Bup-IR) and an extended-release formulation (Bup-ER) in both sexes of 4 different strains of mice (C57BL/6, CD-1, BALB/c, and CB17 SCID) commonly used for dermatology and oncology research at our institution. Skin at the injection site was evaluated for 7 days postinoculation and scored for reactions and then collected for histopathologic analyses. Body weights were evaluated at 1 and 4 days postinoculation. We hypothesized that the administration of Bup-ER would provide a longer duration of blood drug concentration (>1 ng/mL; minimum analgesia threshold) compared with single-dose Bup-IR. We analyzed the standard dose for Bup-IR (0.3 mg/kg) and for Bup-ER (1 mg/kg), along with saline vehicle with blood collected at 1, 4, 24, 48, 72, and 96 hours following administration of Bup-ER and 0.25, 0.5, 1, 2, 3, 6, 9, 12, and 24 hours following administration of Bup-IR using MS. Bup-ER and Bup-IR levels were consistent among sexes of a given strain but varied between strains. Skin reactions, body weight loss, and histopathologic changes were greater in the Bup-ER-treated mice with some sex and strain differences. Due to changes found on histopathology of the skin sections taken from the injection site for Bup-ER-inoculated mice, a separate study to determine cytokine release following Bup-ER injection was performed and revealed only minor changes in a few cytokines. In conclusion, Bup-ER provided longer duration analgesia (>1 ng/mL) compared with Bup-IR. Based on differences found in the strains of mice evaluated, we recommend performing pharmacokinetic analyses for a given strain to determine the best dosing frequency and dose of buprenorphine (IR or ER) for procedures that require analgesia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.